Walleye Capital
EGRX

Walleye Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Walleye Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,000
Closed -$60K – 1821
2019
Q4 		$60K Buy
+1,000
New +$59.6K ﹤0.01% 1481
2019
Q2 		– Sell
-1,800
Closed -$91K – 2138
2019
Q1 		$91K Buy
+1,800
New +$80.1K 0.02% 1064

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital's EGRX Position: Q2 2023 in Review

Walleye Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 16,455 shares — an estimated $467K sold.

Walleye Capital first reported a position in EGRX in Q1 2019 and held it in 7 quarters. The position peaked at $467K in Q1 2023. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • Walleye Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Walleye Capital sold 16,455 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $467K.
  • Walleye Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2019 and held it in 7 quarters.
  • Walleye Capital's Eagle Pharmaceuticals, Inc. position peaked at $467K in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Walleye Capital's 13F filing for Q2 2023, filed 14 Aug 2023.